

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) An antagonist that inhibits angiogenesis by modifying protein-protein interactions, ~~wherein the protein-protein interactions comprise interactions between at least one amino acid sequence within matrix metalloproteinase 9 (MMP-9) and at least one amino acid within a β 1-containing integrin, wherein said antagonist is an antibody or a peptide.~~

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Previously presented) The antagonist of claim 1 wherein the protein-protein interactions cause MMP-9 to bind to the β 1-containing integrin.

6. (Previously presented) The antagonist of claim 1 wherein the β 1-containing integrin is α 5 β 1 integrin.

7. (Canceled)

8. (Original) The antagonist of claim 1 wherein the protein-protein interactions cause co-localization of the first protein and the second protein on a cell surface or a blood vessel.

9. (Original) The antagonist of claim 1 wherein said antagonist inhibits angiogenesis.

10. (Original) The antagonist of claim 1 wherein said antagonist inhibits tumor growth.

11. (Original) The antagonist of claim 1 wherein said antagonist inhibits metastasis.

12. (Original) The antagonist of claim 1 wherein said antagonist inhibits a disease state.

13. (Original) The antagonist of claim 12 wherein the disease is psoriasis, macular degeneration, a neurological disease, or restenosis in a tissue.

14. (Original) The antagonist of claim 1 wherein said antagonist is a monoclonal antibody.

15. (Previously presented) The antagonist of claim 14 wherein said monoclonal antibody ~~is monoclonal antibody FM155, which~~ specifically binds to a polypeptide consisting of the ~~having a~~ sequence of SEQ ID NO: 1.

16. (Previously presented) An antagonist that inhibits angiogenesis by modifying protein-protein interactions, wherein the protein-protein interactions comprise interactions between at least one amino acid sequence within a first protein and at least one amino acid within a second protein, wherein said antagonist is an antibody ~~has the binding specificity for at least one target of monoclonal antibody FM155, which~~ specifically binds to a polypeptide consisting of the ~~having a~~ sequence of SEQ ID NO: 1.

17. (Original) The antagonist of claim 1 wherein the antagonist is a polyclonal antibody.

18. (Withdrawn) The antagonist of claim 1 wherein the antagonist is a polypeptide, a linear peptide or a cyclic peptide.

19. (Withdrawn) The antagonist of claim 1 wherein the antagonist is a non-peptidic compound.

20. (Withdrawn) The antagonist of claim 1 wherein the antagonist is a small organic compound.

21. (Withdrawn) The antagonist of claim 1 wherein the antagonist is an oligonucleotide.

22. (Original) The antagonist of claim 1 wherein the antagonist is a humanized or chemically modified monoclonal antibody.

23. (Original) The antagonist of claim 1 wherein the antagonist is a fragment of a monoclonal antibody.

24. (Original) The antagonist of claim 1 wherein the antagonist is conjugated to cytotoxic or cytostatic agents.

25. (New) The antagonist of claim 15 wherein said monoclonal antibody is monoclonal antibody FM155.

26. (New) The antagonist of claim 16 wherein the antagonist is monoclonal antibody FM155.